Revvity DAMGO, -, 250uCi (9.25MBq)

DAMGO is a synthetic agonist with high selectivity for the mu-opioid receptor (MOR). These receptors are a group of GPCRs that are involved in analgesia, and are potential drug targets for drug addiction.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET902:

1. Page, K., Besret, L., Jain, M. et Al. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and µ-opioid receptor binding in the basal ganglia. Exp Brain Res (2000) 130: 142.
2. Jessica R. Gugusheff, Sung Eun Bae, Alexandra Rao, Iain J. Clarke, Lucilla Poston, Paul D. Taylor, Clive W. Coen, Beverly S. Muhlhausler, Sex and age-dependent effects of a maternal junk food diet on the mu-opioid receptor in rat offspring, In Behavioural Brain Research (2016) 301: 124-131.